Introduction {#s1}
============

A sustained rise in cytosolic calcium is necessary for nuclear translocation of calcium-dependent transcription factors such as nuclear factor of activated T cell (NFAT) ([@bib11]; [@bib47]; [@bib72]; [@bib37]; [@bib67], [@bib65]; [@bib12]). NFAT proteins are essential for the development of several tissues but have been found to be dispensable for thymic development and function of Foxp3 regulatory T cells (Tregs) ([@bib13]; [@bib12], [@bib11]; [@bib59]; [@bib62]). The role of proteins directly involved in sustained calcium influx, however, remains less well established. Specifically, genetic ablation of ORAI1, the pore forming subunit of calcium release activated calcium (CRAC) channels ([@bib64], [@bib63]; [@bib50]), partially inhibits T cell effector cytokines in mice and does not affect Foxp3 Treg development ([@bib66]; [@bib67]; [@bib22]; [@bib39]). The role of ORAI2 as well as ORAI3, the two closely related homologs of ORAI1 that are highly expressed in mouse T cells remains unestablished in mice and humans although all ORAIs are capable of reconstituting CRAC currents in vitro ([@bib41]; [@bib34]; [@bib14]).

STIM1 and STIM2, the ER resident calcium sensor proteins, are required for ER calcium release, Orai1 activation and T lymphocyte effector functions ([@bib45]). However, ablation of STIMs, but not ORAIs, affects thymic development of Tregs ([@bib46]; [@bib39]) and ablation of STIMs, but not ORAI1, results in multi-organ autoimmunity in mice and humans ([@bib45]; [@bib39]; [@bib51]). Because STIMs perform several additional functions such as regulation of calcium selectivity of ORAI1 channels ([@bib40]) as well as inhibition of voltage-gated calcium channel Cav1.2 ([@bib68]; [@bib48]), role of sustained calcium influx or store-operated calcium entry (SOCE) in the development of Tregs and autoimmunity remains correlative ([@bib45], [@bib46]). Likewise, the phenotypes of human patients harboring different Stim and Orai mutations range from immunodeficiency to autoimmunity and cancer. Despite this diversity, all phenotypes are currently correlated with reduced SOCE ([@bib51]).

We have previously shown that α-soluble NSF-attachment protein (α-SNAP), a cytosolic protein traditionally studied in the context of soluble NSF attachment protein receptor (SNARE) complex disassembly and membrane trafficking ([@bib10]), directly binds Stim1 and Orai1 and is necessary for the functional assembly and ion specificity of multimeric Orai1 channels ([@bib42]; [@bib32]). In addition, α-SNAP has been implicated in AMP kinase (AMPK) inhibition and zippering of SNAREs in vitro ([@bib49]; [@bib3]; [@bib69]). SNAREs play a direct role in exocytosis and are therefore required for cytotoxic T, natural killer and mast cell degranulation ([@bib2]; [@bib52]; [@bib23]; [@bib57]). However, the role of α-SNAP is less clear in vivo, and remains unexplored in the immune system. α-SNAP deletion is embryonic lethal in mice and a hypomorphic missense mutation in α-SNAP, hydrocephalus with hopping gait, *(Napa^hyh/hyh^)* has been previously reported to cause neuro-developmental defects ([@bib4]; [@bib6]; [@bib24]).

Here, we show that reduced expression of α-SNAP causes unexpected defects in CD4 T cell signaling, gene expression and Foxp3 Treg differentiation. Using RNAi-mediated ablation of Orai1 in *Napa^hyh/hyh^* CD4 T cells and monensin treatment of wildtype CD4 T cells, we demonstrate that Orai1 mediated sodium influx, but not reduced SOCE, depletes \[ATP\]~i~ in T cell receptor (TCR) stimulated *Napa^hyh/hyh^* CD4 T cells. Furthermore, we find that depletion of \[ATP\]~i~ levels disrupts mTORC2 activation which, in turn, inhibits NFκB activation and differentiation of Foxp3 Tregs in *Napa^hyh/hyh^* mice in vivo as well as in vitro. Therefore, analysis of α-SNAP deficient mice reveals that sodium permeation *via* Orai1 disrupts a novel signaling node and could provide alternate mechanistic insights into the diversity of phenotypes observed in Stim and Orai mutant human patients.

Results {#s2}
=======

*Napa^hyh/hyh^* mice harbor severe defects in the production of CD4 T cell effector cytokines {#s2-1}
---------------------------------------------------------------------------------------------

Mice bearing *Napa^hyh/hyh^* mutation on a mixed background have been characterized previously in the context of neurodevelopmental disorders ([@bib4]; [@bib6]; [@bib24]). We backcrossed *Napa^hyh/hyh^* mice on to C57BL/6 background and found that homozygous mutant *Napa^hyh/hyh^* mice were significantly smaller in size and died perinatally, within 2--3 weeks. To overcome the issue of perinatal lethality, we generated fetal liver chimeras using irradiated CD45.1+ congenic recipients reconstituted with CD45.2+ wildtype or *Napa^hyh/hyh^* E15.5 embryos. We analyzed fetal liver chimeras at 8--12 week post-transfer and found that the reconstitution efficiency and number of thymocytes ([Figure 1A](#fig1){ref-type="fig"}) and splenocytes ([Figure 1B](#fig1){ref-type="fig"}) was comparable in wildtype (WT) and *Napa^hyh/hyh^* chimeras. Relative abundance of CD4 and CD8 T cells in the thymus ([Figure 1C](#fig1){ref-type="fig"}) and spleen ([Figure 1D](#fig1){ref-type="fig"}) was also normal in *Napa^hyh/hyh^* fetal liver chimeras. Therefore, we performed all the subsequent analysis of wildtype and *Napa^hyh/hyh^* CD4 T cells and Foxp3 Tregs using fetal liver chimeras, unless otherwise specified.10.7554/eLife.25155.002Figure 1.*Napa^hyh/hyh^* mice harbor severe defects in the production of CD4 T cell effector cytokines.(**A** and **B**) Representative FACS profile showing the reconstitution efficiency and average cell yields from the thymus (**A**) and spleen (**B**) of WT (black) and *Napa^hyh/hyh^* (red) fetal liver chimeric mice. (n = 25). (**C** and **D**) Representative FACS profile showing the percentage of CD4+, CD8+ single and double positive thymocytes in CD45.2+ gated cells from WT and *Napa^hyh/hyh^* chimera thymus (**C**) and spleen (**D**). (n = 10). (**E**) Representative Western blot for α-SNAP in whole cell lysates prepared from WT and *Napa^hyh/hyh^* lymph node cells. (n \> 5). (**F**) FACS profiles showing surface staining of WT (black) and *Napa^hyh/hyh^* (red) spleen cells with anti-CD4, anti-CD8, anti-CD3, anti-CD28 and anti-TCRβ antibodies respectively. (n = 5). (**G**) FACS profiles of resting (thin lines) and receptor stimulated (thick lines); WT (black) and *Napa^hyh/hyh^* (red) CD4 T cells stained for various activation markers. (n = 3). (**H--J**) FACS profiles showing intracellular staining for IL-2 (**H**,**J**) and TNF-α (**I**,**J**) in WT (black) and *Napa^hyh/hyh^* (red) CD4 T cells 6 hr post-stimulation. Grey peak shows unstimulated control. (n = 5 repeats from five chimeras each). (**K--M**) FACS profiles showing intracellular cytokine staining for Th1 (**K**,**M**) and Th2 (**L**,**M**) signature cytokines in polarized WT (black) and *Napa^hyh/hyh^* (red) CD4 T lymphocytes. Grey peak shows undifferentiated control. (n = 3). (**N**,**O**) CFSE dilution profiles (**N**) and their quantifications (**O**), showing proliferation of WT (black) and *Napa^hyh/hyh^* (red) CD4 T cells in response to plate bound anti-CD3 and anti-CD28 antibodies. Light traces show unstimulated control. (n = 3). (**P**) Representative plot showing proliferation of WT (black) and *Napa^hyh/hyh^* (red) splenocytes in response to soluble anti-CD3 and anti-CD28, estimated using ^3^H thymidine incorporation. (n = 3). (See also [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.25155.002](10.7554/eLife.25155.002)10.7554/eLife.25155.003Figure 1---figure supplement 1.Bar plots showing the average MFIs of the intracellular staining for T-bet and GATA-3 in Th1 and Th2 differentiated WT (black) and *Napa^hyh/hyh^* (red) CD4 T cells, respectively. (n = 3).**DOI:** [http://dx.doi.org/10.7554/eLife.25155.003](10.7554/eLife.25155.003)

α-SNAP null mice are embryonic lethal and, in accordance with previous reports, *Napa^hyh/hyh^* CD4 T cells showed \~40% depletion of α-SNAP levels ([Figure 1E](#fig1){ref-type="fig"}). Given the role of α-SNAP in SNARE recycling ([@bib10]), we first compared the levels of cell surface receptors. Surprisingly, surface expression TCR and co-receptors was normal in *Napa^hyh/hyh^* peripheral CD4 T cells ([Figure 1F](#fig1){ref-type="fig"}). Resting *Napa^hyh/hyh^* T lymphocytes showed largely normal surface expression of CD25, CD44 and CD69 and their up-regulation following receptor-mediated stimulation was comparable to WT ([Figure 1G](#fig1){ref-type="fig"}).

CRAC channel components, Orai1 and Stim1 are necessary for optimal production and secretion of several T cell effector cytokines ([@bib66]; [@bib67]; [@bib22]; [@bib45]). However, given a partial depletion of α-SNAP in *Napa^hyh/hyh^* mice, we first sought to determine whether *Napa^hyh/hyh^* CD4 T cells showed defects in the production of effector cytokines. Surprisingly, we found significant defects in IL-2 ([Figure 1H and J](#fig1){ref-type="fig"}) and TNF-α production by TCR-stimulated *Napa^hyh/hyh^* CD4 T cells ([Figure 1I and J](#fig1){ref-type="fig"}). *Napa^hyh/hyh^* CD4 T cells cultured under T helper 1 (Th1) polarizing conditions showed a minor defect in IFN-γ production ([Figure 1K and M](#fig1){ref-type="fig"}), however, we observed a robust defect in IL-4 expression in Th2-polarized *Napa^hyh/hyh^* CD4 T cells ([Figure 1L and M](#fig1){ref-type="fig"}). Intracellular levels of T-bet or Gata-3 did not appear to be significantly altered in *Napa^hyh/hyh^* mice ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Furthermore, *Napa^hyh/hyh^* CD4 T cells ([Figure 1N--1O](#fig1){ref-type="fig"}) and splenocytes ([Figure 1P](#fig1){ref-type="fig"}) showed a partial defect in anti-CD3-induced proliferation. Taken together, these data demonstrate that *Napa^hyh/hyh^* CD4 T lymphocytes harbor a significant defect in the production of several key effector cytokines, while exhibiting normal levels of cell surface receptors.

*Napa^hyh/hyh^* mice harbor significant defects in the differentiation of Foxp3 regulatory T cells in vivo and in vitro {#s2-2}
-----------------------------------------------------------------------------------------------------------------------

*Stim1-/-Stim2-/-* mice ([@bib46]), but neither *Orai1-/-* ([@bib39]) nor *Nfatc1-/-Nfatc2-/-* mice ([@bib62]), harbor defects in the development of thymic Foxp3 Tregs. Interestingly, analysis of *Napa^hyh/hyh^* fetal liver chimeras of 8--12 weeks showed lower percentage ([Figure 2A](#fig2){ref-type="fig"}) as well as total number ([Figure 2---source data 1](#SD1-data){ref-type="supplementary-material"}) of thymic Foxp3 Tregs when compared to WT. Mixed fetal liver chimeras of WT and *Napa^hyh/hyh^* showed further reduced percentages of *Napa^hyh/hyh^* Foxp3 Tregs in the thymus ([Figure 2B](#fig2){ref-type="fig"}) as well as peripheral lymphoid tissues ([Figure 2C](#fig2){ref-type="fig"}) and *Napa^hyh/hyh^* Foxp3 Tregs consistently showed lower surface expression of CD44 ([Figure 2D](#fig2){ref-type="fig"}) and GITR ([Figure 2E](#fig2){ref-type="fig"}). These data suggest additional potential defects in the homing ([@bib36]) and in vivo expansion of Foxp3 Tregs ([@bib54]; [@bib18]; [@bib33]). Indeed, lamina propria of *Napa^hyh/hyh^* chimeras showed further reduced numbers of Foxp3 Tregs ([Figure 2F](#fig2){ref-type="fig"}). Furthermore, in vitro differentiation of *Napa^hyh/hyh^* CD4 T cells also yielded lower percentage ([Figure 2G](#fig2){ref-type="fig"}) and number ([Figure 2---source data 2](#SD2-data){ref-type="supplementary-material"}) of Foxp3 iTregs. Taken together, these data demonstrate a crucial role for α-SNAP in Foxp3+ Treg differentiation in vivo as well as in vitro.10.7554/eLife.25155.004Figure 2.*Napa^hyh/hyh^* mice harbor significant defects in the differentiation of Foxp3 regulatory T cells in vivo and in vitro.(**A**) Representative FACS profiles and dot plot showing the percentage of Foxp3+CD25+ cells in the CD4+CD45.2+ population from WT and *Napa^hyh/hyh^* chimera thymii. (n = 3 with 2 chimeras/experiment). (**B**) Dot plot showing the percentage of WT and *Napa^hyh/hyh^* Foxp3+ cells in mixed chimera thymii. (n = 4 with 2--3 chimeras/experiment). *p* value from paired student's t-test. (**C**) Dot plots showing the percentage of WT and *Napa^hyh/hyh^* Foxp3+ cells in blood, spleen and mesenteric lymph nodes (MLN). (n = 4 with 2--3 chimeras/experiment). (**D**) Representative FACS profile and dot plots showing mean fluorescence intensity (MFI) of surface expression of CD44 on WT (black) and *Napa^hyh/hyh^* (red) Foxp3+ cells from various lymphoid tissues of mixed chimeras. (n = 4 with 2 chimeras/experiment). (**E**) FACS profile and dot plot showing mean fluorescence intensity (MFI) of the surface expression of GITR on WT (black) and *Napa^hyh/hyh^* (red) Foxp3+ cells from spleen. (n = 3). (**F**) Dot plot showing the percentage of WT and *Napa^hyh/hyh^* Foxp3+ cells in the lamina propria CD4 T cells isolated from mixed chimeras. (n = 3 with 2 chimeras/experiment). (**G**) Dot plot showing the normalized percentage of WT (black) and *Napa^hyh/hyh^* (red) Foxp3+ cells in in vitro-differentiated CD4 T cells. (n = 7). *p* value from paired student's t test. (See also [Figure 2---source data 1](#SD1-data){ref-type="supplementary-material"} and [2](#SD2-data){ref-type="supplementary-material"}).**DOI:** [http://dx.doi.org/10.7554/eLife.25155.004](10.7554/eLife.25155.004)10.7554/eLife.25155.005Figure 2---source data 1.Thymic Foxp3 Tregs in WT and *Napa^hyh/hyh^* chimeras.Single cell suspensions were prepared from WT and *Napa^hyh/hyh^* fetal liver chimerathymii, counted and then stained for Foxp3, CD25, CD4, and CD45.2 as described in [Figure 2A](#fig2){ref-type="fig"}. The absolute numbers and percentages of Foxp3+CD25+ cells were then calculated in CD4 and CD45.2 double positive cells.**DOI:** [http://dx.doi.org/10.7554/eLife.25155.005](10.7554/eLife.25155.005)10.7554/eLife.25155.006Figure 2---source data 2.Foxp3 iTregs in WT and *Napa^hyh/hyh^* CD4 T cell cultures.WT and *Napa^hyh/hyh^* CD4 T cells were purified from the spleen and lymph nodes of chimeras and differentiated into Foxp3+ cells in vitro. Shown here are the absolute numbers and percentages of Foxp3 cells obtained from [Figure 2G](#fig2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.25155.006](10.7554/eLife.25155.006)

Orai1-mediated sodium influx inhibits Foxp3 iTreg differentiation by disrupting NFκB activation in *Napa^hyh/hyh^* CD4 T cells {#s2-3}
------------------------------------------------------------------------------------------------------------------------------

We have previously shown that α-SNAP is an integral component of the CRAC channel complex, where it facilitates the functional assembly as well as ion selectivity of Orai1 multimers via specific molecular interactions ([@bib32]). Because *Orai1-/-* mice do not show a defect in Foxp3 regulatory T cell development ([@bib66]; [@bib67]; [@bib22]; [@bib39]), we hypothesized that non-specific sodium permeation *via* Orai1 could lead to reduced generation of thymic and iTregs in *Napa^hyh/hyh^* mice.

In agreement with our previous findings ([@bib42]), stimulation of *Napa^hyh/hyh^* CD4 T cells *via* TCR ([Figure 3A and B](#fig3){ref-type="fig"}) or Thapsigargin (TG) ([Figure 3C](#fig3){ref-type="fig"}) induced lower SOCE. More strikingly though, *Napa^hyh/hyh^*, but not wildtype CD4 T cells, showed rapid and significant sodium entry in response to TCR as well as TG stimulation ([Figure 3D and E](#fig3){ref-type="fig"}). Interestingly, RNAi-mediated depletion of Orai1 in *Napa^hyh/hyh^* cells abolished sodium influx, demonstrating that sodium enters *via* Orai1 in TCR-stimulated *Napa^hyh/hyh^* CD4 T cells ([Figure 3F](#fig3){ref-type="fig"}). Furthermore, replacement of extracellular sodium with a membrane impermeable organic monovalent cation, N-methyl-D-glucamine (NMDG) prevented fluorescence shift of the sodium dye, SBFI ([Figure 3F](#fig3){ref-type="fig"}), establishing its specificity for sodium and the direction of sodium flux in receptor-stimulated CD4 T cells. Of note, treatment of wildtype CD4 T cells with monensin, a non-specific sodium ionophore, induced similar levels of sodium influx ([Figure 3G](#fig3){ref-type="fig"}) when compared to TCR-stimulated *Napa^hyh/hyh^* CD4 T cells.10.7554/eLife.25155.007Figure 3.Orai1-mediated sodium influx inhibits Foxp3 iTreg differentiation by disrupting NFκB activation in *Napa^hyh/hyh^* CD4 T cells.(**A--C**) Representative Fura-2 profiles showing real-time change in average cytosolic calcium levels in WT (black) or *Napa^hyh/hyh^* (red) CD4 T cells stimulated with anti-CD3 antibody (**A** and **B**) (n = 5 with\~50 to 100 cells per experiment) or thapsigargin (TG) (**C**) (n = 3 with\~50 to 100 cells per experiment). Percent SOCE was calculated by normalizing average WT response to 100 and then calculating the % response of *Napa^hyh/hyh^* CD4 T cells. (**D** and **E**) Average SBFI profiles showing real-time change in \[Na\]~i~ of WT (black) and *Napa^hyh/hyh^* (red) CD4 T cells stimulated with anti-CD3 antibody (**D**) (n = 5 with\~50 to 100 cells per experiment) or TG (**E**) (n = 1 with\~50 to 100 cells per experiment). (**F**) Average SBFI profiles of anti-CD3-stimulated WT (black) and *Napa^hyh/hyh^* CD4 T cells treated with scramble (scr) RNAi (red) or Orai1 RNAi (blue); (magenta) anti-CD3-stimulated *Napa^hyh/hyh^* T cells where \[Na\]~e~ was replaced with NMDG. (n = 1 with\~50 to 100 cells per experiment). (**G**) SBFI profiles of WT CD4 T cells, treated with Monensin (red) or untreated (black). (n = 1 with\~50 to 100 cells per experiment). (**H**,**I**) Western blot for cytosolic and nuclear NFAT1 and NFκB p65 (**H**) or c-Rel (**I**) in receptor-stimulated WT and *Napa^hyh/hyh^* CD4 T cells. (n = 4). (**J**,**K**) Western blot for total and phospho-Lck, ZAP-70 and PLC- γ (**J**) and total and phospho-Erk1/2, p38 and Jnk (**K**) in receptor-stimulated WT and *Napa^hyh/hyh^* CD4 T cell WCLs. (n = 3). (**L**) Representative Fura-2 profiles showing real-time change in average cytosolic calcium levels in scr (black) or Orai1 RNAi treated (red) CD4 T cells stimulated with anti-CD3 antibody. (n = 2 with\~50 to 100 cells per experiment). (**M**,**N**) Western blot for cytosolic and nuclear NFAT (**M**) and NFκB p65 (**N**) in receptor-stimulated scr or Orai1 RNAi (Orai1) treated WT CD4 T cells. (**O**) Representative dot plot showing the normalized percentage of Foxp3+ cells in scr (black) and Orai1 RNAi treated (red) CD4 T cells differentiated in vitro. (n = 3), *p* value from paired student's t-test. (**P**) FACS profiles showing intracellular IL-2 expression in WT CD4 T cells, receptor-stimulated in the presence (red) or absence (black) of monensin. (n = 2). (**Q**,**R**) Western blot for nuclear NFAT1 (**Q**) and NFκB p65 (**R**) in receptor stimulated WT CD4 T cells with or without monensin. (n = 2). (**S**) Bar plot showing % Foxp3+ cells differentiated in vitro, in the absence or presence of different doses of monensin. (n = 3).**DOI:** [http://dx.doi.org/10.7554/eLife.25155.007](10.7554/eLife.25155.007)

In agreement with reduced SOCE, we observed that nuclear translocation of NFAT was defective in *Napa^hyh/hyh^* CD4 T cells ([Figure 3H](#fig3){ref-type="fig"}). However, nuclear translocation of NFκB p65 and c-Rel transcription factors was also severely inhibited in TCR-stimulated *Napa^hyh/hyh^* CD4 T cells ([Figure 3H and I](#fig3){ref-type="fig"}), although we found no significant defect in T cell receptor-proximal signaling events or MAPK activation ([Figure 3J and K](#fig3){ref-type="fig"}). TCR proximal signaling requires an interplay of several cell surface receptors, co-receptors and membrane proximal kinases, thus further reinforcing our observations that membrane receptor signaling events remain unperturbed in *Napa^hyh/hyh^* T cells.

To determine whether defects in NFκB translocation were due to reduced SOCE or non-selective sodium influx, we first depleted Orai1 expression in CD4 T cells using RNAi. Orai1 depletion lead to reduced SOCE ([Figure 3L](#fig3){ref-type="fig"}) and nuclear translocation of NFAT ([Figure 3M](#fig3){ref-type="fig"}). However, NFκB activation ([Figure 3N](#fig3){ref-type="fig"}) and iTreg differentiation ([Figure 3O](#fig3){ref-type="fig"}) were normal in Orai1-depleted CD4 T cells. On the other hand, stimulation of wildtype CD4 T cells in the presence of monensin did not affect IL-2 expression ([Figure 3P](#fig3){ref-type="fig"}) or NFAT activation ([Figure 3Q](#fig3){ref-type="fig"}), but inhibited NFκB activation ([Figure 3R](#fig3){ref-type="fig"}) and iTreg differentiation ([Figure 3S](#fig3){ref-type="fig"}). Taken together, these data show that TCR-induced non-selective sodium influx *via* Orai1 inhibits NFκB activation to restrict Foxp3 T cell development in *Napa^hyh/hyh^* mice.

TCR-induced non-specific sodium influx depletes \[ATP\]~i~ in *Napa^hyh/hyh^* CD4 T cells {#s2-4}
-----------------------------------------------------------------------------------------

Next, by examining additional signaling events in TCR-stimulated *Napa^hyh/hyh^* CD4 T cells, we sought to understand the molecular basis by which NFκB activation is defective. The sodium potassium ATPase (Na K ATPase) maintains resting membrane potential by pumping out intracellular sodium using ATP hydrolysis and can consume \~30--40% of cellular ATP at any given time in resting cells ([@bib60]). Hence, we reasoned that TCR-induced abnormal sodium entry could cause an acute metabolic burden in *Napa^hyh/hyh^* cells and measured the change in \[ATP\]~i~ levels in resting and TCR-stimulated CD4 T cells at different time points post stimulation. Interestingly, wildtype CD4 T cells showed a rapid and significant rise in \[ATP\]~i~ upon TCR ligation ([Figure 4A](#fig4){ref-type="fig"}). *Napa^hyh/hyh^* CD4 T cells failed to show this increase but instead showed a sustained drop in \[ATP\]~i ~post-stimulation ([Figure 4A](#fig4){ref-type="fig"}).10.7554/eLife.25155.008Figure 4.TCR-induced non-specific sodium influx depletes \[ATP\]~i~ in *Napa^hyh/hyh^* CD4 T cells.(**A**) Percent change in intracellular ATP levels \[ATP\]~i~ in anti-CD3-stimulated WT and *Napa^hyh/hyh^* CD4 T cells, measured at different times post-stimulation. (n = 6). (**B**) Percent change in \[ATP\]~i~ in WT CD4 T cells, stimulated with anti-CD3 in the presence or absence of Monensin. (n = 2). (**C**) Percent change in \[ATP\]~i~ in anti-CD3-stimulated WT and *Napa^hyh/hyh^* CD4 T cells, treated with scramble (scr) or Orai1 RNAi (Orai1). (n = 2). (**D**) FACS profiles of WT (black) and *Napa^hyh/hyh^* (red) CD4 T cells stained with Mitotracker green. (n = 2). (**E--J**) OCR and ECAR profiles of naive (**E**,**F**), TCR receptor stimulated for 6 hr (**G**,**H**), or TH0 (**I**,**J**) WT (black) and *Napa^hyh/hyh^* (red) CD4 T cells. (n = 2 each).**DOI:** [http://dx.doi.org/10.7554/eLife.25155.008](10.7554/eLife.25155.008)

To determine whether the defect in \[ATP\]~i~ rise was due to sodium influx, we exchanged extracellular sodium with NMDG, and found that the \[ATP\]~i~ rise was largely restored in *Napa^hyh/hyh^* T cells ([Figure 4A](#fig4){ref-type="fig"}). Stimulation of wildtype CD4 T cells in the presence of monensin also depleted \[ATP\]~i~ levels ([Figure 4B](#fig4){ref-type="fig"}) and RNAi-mediated depletion of Orai1 in *Napa^hyh/hyh^* CD4 T cells largely restored the \[ATP\]~i~ depletion ([Figure 4C](#fig4){ref-type="fig"}).

Naïve CD4 T cells depend on oxidative phosphorylation to generate \[ATP\]~i~. To determine whether the mitochondrial number and function were normal in *Napa^hyh/hyh^* CD4 T cells, we stained *Napa^hyh/hyh^* CD4 T cells with MitoTracker green and found that their mitochondrial content was normal ([Figure 4D](#fig4){ref-type="fig"}). Oxygen consumption rate (OCR), extracellular acidification rate (ECAR) and the respiratory capacities of naïve ([Figure 4E and F](#fig4){ref-type="fig"}), receptor-stimulated ([Figure 4G and H](#fig4){ref-type="fig"}) and TH0- differentiated ([Figure 4I and J](#fig4){ref-type="fig"}) *Napa^hyh/hyh^* CD4 T cells were also largely comparable to wildtype T cells. Taken together, these data demonstrate that non-specific sodium influx, but not compromised mitochondrial health, underlies depletion of \[ATP\]~i~ in receptor-stimulated *Napa^hyh/hyh^* CD4 T cells.

Depletion of \[ATP\]~i~ inhibits mTORC2 activation in *Napa^hyh/hyh^* CD4 T cells {#s2-5}
---------------------------------------------------------------------------------

Extracellular ATP \[ATP\]~e~ has been extensively studied in the context of T cell activation ([@bib56]; [@bib30]) autoimmunity and graft versus host disease ([@bib1]; [@bib71]) but the physiological significance of TCR- induced acute rise in \[ATP\]~i~ remains unknown. We hypothesized that although dispensable for TCR proximal signaling ([Figure 3J and K](#fig3){ref-type="fig"}), TCR-induced \[ATP\]~i~ rise could be necessary to support the relatively distal signaling events following TCR activation. Recently, mTORC2 has emerged as a crucial, but complex, player in T cell differentiation ([@bib9]). mTORC2 can sense a variety of upstream signals and according to one report, directly senses ATP and phosphorylates AKT Thr450 in vitro ([@bib8]). The upstream activator of mTORC2 in CD4 T cells, however, remains unestablished ([@bib38]; [@bib43]). Therefore, we assessed the phosphorylation of AKT Ser473, a well-established mTORC2 target in TCR-stimulated *Napa^hyh/hyh^* CD4 T cells. *Napa^hyh/hyh^* CD4 T cells showed significantly reduced phosphorylation of AKT Ser473 ([Figure 5A](#fig5){ref-type="fig"}), but not Thr308 ([Figure 5B](#fig5){ref-type="fig"}), the mTORC1 target site. Furthermore, TCR stimulation of wildtype CD4 T cells in the presence of monensin also blocked AKT Ser473 phosphorylation ([Figure 5C](#fig5){ref-type="fig"}) but not Thr308 ([Figure 5D](#fig5){ref-type="fig"}). In accordance with these observations, phosphorylation of mTORC1 substrate, 4E-BP1 was normal in *Napa^hyh/hyh^* CD4 T cells ([Figure 5E](#fig5){ref-type="fig"}). Of note, Orai1 depletion restored AKT Ser473 phosphorylation in *Napa^hyh/hyh^* CD4 T cells ([Figure 5F](#fig5){ref-type="fig"}) and the levels of mTORC2 complex proteins were largely comparable in WT and *Napa^hyh/hyh^* CD4 T cell WCLs ([Figure 5G](#fig5){ref-type="fig"}). These data demonstrate that Orai1 mediated sodium influx and the consequent drop in \[ATP\]~i~ disrupts TCR-induced mTORC2 activation.10.7554/eLife.25155.009Figure 5.Depletion of \[ATP\]~i~ inhibits mTORC2 activation in *Napa^hyh/hyh^* CD4 T cells.(**A**,**B**) Western blot for total and pS473 (**A**) or pT308 (**B**) phospho-AKT in receptor-stimulated WT and *Napa^hyh/hyh^* CD4 T cell WCLs at different times post-activation. (n = 3). (**C**,**D**) Western blot for total and pS473 phospho-AKT (**C**) or pT308 phospho-AKT (**D**) in WT CD4 T cell receptor stimulated in the presence or absence of monensin. (n = 2). (**E**) Western blot for total and phospho- pT37/46 4E-BP1 in receptor-stimulated WT and *Napa^hyh/hyh^* CD4 T cell WCLs. (**F**) Western blot for total and pS473 phospho-AKT in WCLs of receptor-stimulated WT and *Napa^hyh/hyh^* CD4 T cells, treated with scramble (scr) or Orai1 RNAi (Orai1). (n = 2). (**G**) Western blot for mTORC2 complex proteins in the WCLs of receptor-stimulated WT and *Napa^hyh/hyh^* CD4 T cells. (n = 2).**DOI:** [http://dx.doi.org/10.7554/eLife.25155.009](10.7554/eLife.25155.009)

mTORC2 regulates NFκB activation *via* multiple signaling intermediates in *Napa^hyh/hyh^* CD4 T cells {#s2-6}
------------------------------------------------------------------------------------------------------

mTORC2 has been shown to regulate NFκB activation *via* many different signaling intermediates including AGC kinase, AKT ([@bib38]), PKC-θ and IκB-α ([@bib31]; [@bib58]). Indeed, in addition to AKT Ser473 ([Figure 5A](#fig5){ref-type="fig"}), phosphorylation of PKC-θ ([Figure 6A](#fig6){ref-type="fig"}), IKK-β ([Figure 6B](#fig6){ref-type="fig"}) and IκB-α ([Figure 6C](#fig6){ref-type="fig"}) was also reduced in TCR-stimulated *Napa^hyh/hyh^* CD4 T cells. Of note, similar to AKT Ser473 ([Figure 5F](#fig5){ref-type="fig"}), IκB-α phosphorylation was restored in *Napa^hyh/hyh^* CD4 T cells upon ablation of Orai1 ([Figure 6D](#fig6){ref-type="fig"}). Given that monensin can also inhibit NFκB activation ([@bib16]), our data demonstrate that defective mTORC2 signaling results in the inhibition of nuclear translocation of NFκB in *Napa^hyh/hyh^* CD4 T cells. 10.7554/eLife.25155.010Figure 6.mTORC2 regulates NFκB activation *via* multiple signaling intermediates in *Napa^hyh/hyh^* CD4 T cells.(**A--C**) Western blots for total and pT538 phospho-PKC-θ (**A**), phospho-IKKβ (**B**) and phospho-IκB-α (**C**) in WCLs of receptor-stimulated WT and *Napa^hyh/hyh^* CD4 T cells. (n = 2). (**D**) Western blot for total and phospho-IκB-α in WCLs of receptor-stimulated WT and *Napa^hyh/hyh^* CD4 T cells, treated with scr or Orai1 RNAi. (**E**) Western blot for cytosolic and nuclear FOXO-1 in receptor-stimulated WT and *Napa^hyh/hyh^* CD4 T cells. (n = 3). (**F**) Principal component analysis (PCA) on gene expression data from TCR-stimulated WT and *Napa^hyh/hyh^* CD4 T cell RNA. (n = 2 from 2 independent chimeras each). (**G**) Scatter plot showing the normalized means of gene expression values (RPKM) in *Napa^hyh/hyh^* and WT CD4 T cells after filtering for genes as described in Materials and methods. (**H**) Bar plot showing fold change in the expression of a few representative genes between WT and *Napa^hyh/hyh^* samples from (**F**,**G**) (See also [Figure 6---source data 1](#SD3-data){ref-type="supplementary-material"}).**DOI:** [http://dx.doi.org/10.7554/eLife.25155.010](10.7554/eLife.25155.010)10.7554/eLife.25155.011Figure 6---source data 1.Pathways defective in receptor stimulated *Napa^hyh/hyh^* CD4 T cells. Gene expression data from Figure 6G were subjected to pathway analysis and top 50 pathways that met the criteria described in Materials and methods are shown.**DOI:** [http://dx.doi.org/10.7554/eLife.25155.011](10.7554/eLife.25155.011)

*c-rel-/-* mice harbor a significant defect in the development as well as function of Foxp3 T cells ([@bib25]; [@bib55]; [@bib35]). Paradoxically, ablation of mTORC2 complex proteins enhances Foxp3 T cell development ([@bib15]) ([@bib31]). Indeed, despite a strong defect in c-Rel and NFκB p65 activation, we observed only a partial decrease in *Napa^hyh/hyh^* Foxp3 T cell development in vivo and well as in vitro ([Figure 2](#fig2){ref-type="fig"}). To resolve this conundrum, we explored other known targets of mTORC2 and found that the nuclear export of FOXO-1 was also partially inhibited ([Figure 6E](#fig6){ref-type="fig"}). FOXO-1 is necessary for Foxp3 Treg development ([@bib26]). However, its inactivation was recently shown to be required for the activation and tumor infiltration of Foxp3 Tregs in vivo ([@bib36]). In agreement with those findings, reduced export of FOXO-1 may partially restore Foxp3 expression in *Napa^hyh/hyh^* iTregs, but inhibit their activation and expansion in vivo.

TCR-stimulated *Napa^hyh/hyh^* CD4 T cells show significantly altered gene expression {#s2-7}
-------------------------------------------------------------------------------------

To analyze the cumulative effect of a concomitant defect in the activation of NFAT, NFκB and nuclear export of FOXO-1 on gene expression, we performed RNA sequencing on TCR-stimulated wildtype and *Napa^hyh/hyh^* CD4 T cells ([Figure 6F and G](#fig6){ref-type="fig"}). Principal component analysis (PCA) on *Napa^hyh/hyh^* and WT samples showed that gene expression from *Napa^hyh/hyh^* replicates were highly correlated between themselves and clustered distinctly from wildtype samples ([Figure 6F](#fig6){ref-type="fig"}). \~500 genes from TCR receptor-stimulated *Napa^hyh/hyh^* CD4 T cells were up or downregulated by \>2 fold compared to their expression in WT cells. The list of differentially expressed genes can be found at (<http://dx.doi.org/10.5061/dryad.202fn>).

A scatter plot of these gene expression values from *Napa^hyh/hyh^* and WT samples is shown in [Figure 6G](#fig6){ref-type="fig"} and the average fold change in the expression of a few representative targets of NFκB, NFAT and FOXO-1 are shown in [Figure 6H](#fig6){ref-type="fig"}. We grouped the differentially expressed genes into pathways using a pathway analysis software. The non-redundant pathways with at least 10% representation of total genes were considered significantly disrupted and top 50 of those are listed in ([Figure 6---source data 1](#SD3-data){ref-type="supplementary-material"}). Thus, receptor-induced non-specific sodium influx disrupts a novel \[ATP\]~i~→ mTORC2 signaling node in *Napa^hyh/hyh^* CD4 T cells, contributing to wide-spread and severe defects in CD4 T cell gene expression, effector cytokine production and Foxp3 regulatory T cell development. To our knowledge, an early rise in \[ATP\]~i~ levels upon TCR stimulation, its sensitivity to sodium permeation and its direct role in the activation of mTORC2 signaling node have not been reported previously.

Ectopic expression of α-SNAP can restore defects in *Napa^hyh/hyh^* CD4 T cell effector cytokine production {#s2-8}
-----------------------------------------------------------------------------------------------------------

Previous characterization of developmental defects in the neuroepithelium of *Napa^hyh/hyh^* mice has suggested that *hyh* mutation causes reduced expression of α-SNAP due to mRNA instability, but M105I α-SNAP has normal function ([@bib6]). Indeed, similar to *Napa^hyh/hyh^* CD4 T cells, RNAi-mediated reduction of α-SNAP expression inhibited SOCE ([Figure 7A](#fig7){ref-type="fig"}) and the expression of key effector cytokines ([Figure 7B](#fig7){ref-type="fig"}) in primary CD4 T cells. Yet, some recent studies have reported that purified M105I α-SNAP protein displays altered function in vitro ([@bib53]; [@bib49]). Therefore, we wondered whether protein intrinsic functional defects in M105I α-SNAP contribute to *Napa^hyh/hyh^* immunodeficiency. To test this, we reconstituted *Napa^hyh/hyh^* CD4 T cells with WT or M105I α-SNAP. Both WT as well as M105I mutant α-SNAP fully restored intracellular IL-2 production ([Figure 7C](#fig7){ref-type="fig"}) as well as SOCE ([Figure 7D](#fig7){ref-type="fig"}) in *Napa^hyh/hyh^* T cells. Consistent with these data, purified M105I α-SNAP protein bound to Stim1 and Orai1 as efficiently as WT α-SNAP in pull down assays in vitro ([Figure 7E](#fig7){ref-type="fig"}). Further, ectopic expression of M105I α-SNAP in HEK 293 cells revealed its cytosolic localization in resting cells ([Figure 7F](#fig7){ref-type="fig"}) as well as co-clustering with Stim1 in ER-PM junctions of store-depleted cells ([Figure 7G](#fig7){ref-type="fig"}), identical to WT α-SNAP localization patterns observed previously ([@bib42]). Taken together, these data show that M105I α-SNAP is functionally similar to WT α-SNAP in its ability to support SOCE and CD4 T cell gene expression.10.7554/eLife.25155.012Figure 7.Ectopic expression of α-SNAP can restore defects in *Napa^hyh/hyh^* CD4 T cells.(**A**) Average cytosolic calcium levels, measured using FURA 2AM, in scr (black) and α-SNAP RNAi (red)-treated cells stimulated with anti-CD3 antibody to measure SOCE. (n = 3 with \~50 to 100 cells per experiment). (**B**) Quantitative PCR to estimate the expression of key effector cytokines in scr (black) and α-SNAP RNAi (red)-treated Th0 cells. (n = 2 repeats; samples from 3 repeats of RNAi). (**C**) Representative FACS profiles showing intracellular IL-2 staining in WT and *Napa^hyh/hyh^* CD4 T cells reconstituted with EV, WT or M105I α-SNAP. (n = 3). (**D**) Average cytosolic calcium levels, measured using FURA 2AM, in anti-CD3- stimulated WT and *Napa^hyh/hyh^* CD4 T cells expressing empty vector (EV), WT or M105I α-SNAP. (n = 2 with \~50 to 200 cells each). (**E**) Western blot showing in vitro binding of WT and M105I α-SNAP to Stim1 and Orai1. (n = 2). (**F**) Confocal images of HEK293 cells expressing WT or M105I α-SNAP and stained with anti-α-SNAP antibody and DAPI (Scale bar 10 μm). (n = 2; 5 to 6 cells/ per group/ experiment). (**G**) TIRF images of store-depleted HEK 293 cells co-expressing CFP-Stim1 and YFP-tagged WT or M105I α-SNAP. (Scale bar 10 μm). (n = 2 with 5 to 6 cells/ per group/ experiment).**DOI:** [http://dx.doi.org/10.7554/eLife.25155.012](10.7554/eLife.25155.012)

[Figure 8](#fig8){ref-type="fig"} summarizes the signaling nodes affected by TCR-induced non-specific sodium influx in α-SNAP deficient, *Napa^hyh/hyh^* CD4 T cells contributing to severely altered gene expression, reduced production of CD4 T cell effector cytokines and Foxp3 Treg development.10.7554/eLife.25155.013Figure 8.Summary of signaling nodes affected by TCR induced non-specific sodium influx.**DOI:** [http://dx.doi.org/10.7554/eLife.25155.013](10.7554/eLife.25155.013)

Discussion {#s3}
==========

We have shown that TCR-induced, Orai1-mediated sodium influx disrupts a novel ATP- dependent signaling cascade necessary for the development of Foxp3 regulatory T cells. High extracellular sodium has been previously shown to upregulate T helper 17 differentiation ([@bib73]; [@bib27]). However, to our knowledge, signaling and phenotypic defects resulting from TCR-induced non-specific sodium influx *via* a well-characterized calcium channel have not been explored previously. Given that deletion or functional ablation of Orai1 inhibits a linear signaling pathway culminating in NFAT activation ([@bib19]), *Napa^hyh/hyh^* mice would be an excellent model for further analyses of in vivo phenotypes resulting from permeation and ion selectivity defects in CRAC channels of mice and humans.

Our findings may also provide mechanistic insights into the previous association of elevated expression of α-SNAP with some aggressive forms of colorectal cancer ([@bib21]). Likewise, monensin-mediated inhibition of Foxp3 iTreg development could, in part, explain the mechanisms underlying its effective re-purposing in the treatment of several different types of cancers ([@bib16]) ([@bib61]).

The Na K ATPase is ubiquitously expressed and during periods of heightened cellular activity, such as action potentials in neurons, it is estimated to consume \>70% of \[ATP\]~i~. ATP hydrolysis is therefore used as a reliable readout for the Na K ATPase activity ([@bib70]). Indeed, sodium influx in TCR-stimulated *Napa^hyh/hyh^* CD4 T cells correlated well with reduced \[ATP\]~i~ levels in our study and no additional defects were observed in the mitochondrial content or morphology ([@bib32]). Therefore, it is reasonable to conclude that depletion of \[ATP\]~i~ resulted from increased Na K ATPase activity in receptor-stimulated *Napa^hyh/hyh^* CD4 T cells. Because Orai1 ablation prevented sodium influx, \[ATP\]~i~ depletion and reversed mTORC2 signaling defects in *Napa^hyh/hyh^* CD4 T cells, these data conclusively demonstrate that sodium permeation *via* Orai1 depletes \[ATP\]~i~.

Following antigen receptor stimulation, surplus \[ATP\]~i~ has been shown to get exported from T cells and bind P2X receptors to sustain calcium influx in an autocrine manner ([@bib56]; [@bib74]). Thus, a decrease in \[ATP\]~i~ could further compound the defect in sustained calcium flux and NFAT activation in *Napa^hyh/hyh^* CD4 T cells.

Genetic ablation of individual components of mTORC2 complex has demonstrated its important role in CD4 T cell homeostasis as well as helper T cell and Foxp3 Treg differentiation ([@bib20]; [@bib7]; [@bib38]; [@bib15]; [@bib43]). However, because the upstream activator of mTORC2 was unestablished in T cells ([@bib43]; [@bib38]), its role could be more complex and context-dependent in vivo. Adding to this complexity, mTORC2 regulates a variety of downstream targets ([@bib28], [@bib29]). For instance, mTORC2→NF-κB signaling is involved in cancer progression downstream of EGFR ([@bib58]). Intriguingly, while mTORC2 inhibits Foxp3 Treg differentiation ([@bib15]), NFκB has been shown to be necessary for Treg development and function ([@bib25]; [@bib55]; [@bib35]). Likewise, FOXO-1 has a dual role in Treg development versus activation ([@bib26]; [@bib36]). While its ablation inhibits Foxp3 Treg development, its inactivation is necessary for Treg activation, homing and tumor infiltration ([@bib26]; [@bib36]). Therefore, future analyses of *Napa^hyh/hyh^* mice will help in evaluating the consequences of simultaneous inhibition of NFAT and mTORC2-dependent signaling pathways on CD4 T cell homeostasis, differentiation and function in specific physiological and disease contexts in vivo.

It is intriguing that membrane trafficking of TCR and co-receptors was normal in *Napa^hyh/hyh^* CD4 T cells. This result can be explained by considering a competitive binding model for the interactions of α-SNAP with membrane trafficking proteins *versus* the Orai-Stim complex. Indeed, a significant fraction of α-SNAP has been shown to be sequestered by its binding to monomeric syntaxins in resting cells ([@bib5]; [@bib53]). Furthermore, we have found that the affinity of α-SNAP for SNAREs is significantly higher when compared to Stim1 and Orai1 (Bhojappa et al. unpublished findings). Higher affinity and constitutive association of α-SNAP with SNAREs could explain the relatively intact membrane trafficking of proteins in *Napa^hyh/hyh^* CD4 T cells which harbor only a partial depletion of α-SNAP levels when compared to more robust defects in supporting CRAC channel function. ([@bib4]; [@bib6]; [@bib24]).

In summary, we have identified a novel \[ATP\]~i~→ mTORC2-dependent signaling axis, demonstrated its requirement for CD4 and Foxp3 regulatory T cell differentiation and established its sensitivity to non-specific sodium influx *via* Orai1.

Materials and methods {#s4}
=====================

Mice  {#s4-1}
-----

*Napa^hyh/hyh^* (RRID: [MGI:3033683](https://scicrunch.org/resolver/MGI:3033683)) mice were obtained from Jackson Laboratory (Bar Harbor, ME) (strain number: 001035, strain name: B6C3Fe *a/a-Napa^hyh/hyh^*/J) and backcrossed onto C57BL/6J until they were \>99.4% C57BL/6J, with the help of speed congenics core (RDCC) of the Washington University. All animal experiments were performed according to the guidelines of the Animal Studies Committee of the Washington University School of Medicine in Saint Louis, Protocol Approval Number 20150289.

Genotyping {#s4-2}
----------

For genotyping *Napa^hyh/hyh^* mice a Custom TaqMan SNP Genotyping Assay developed by Applied Biosystems (Foster City, CA) was used. Forward primer: TCTTTGCTCCCTAGAGGCCATTA, Reverse primer: CAAGCAACCCTTACCATGTCTGTAT, Reporter 1 (VIC): CTGTCTGATGAGAGCAA, Reporter 2 (FAM): ACTGTCTGATAAGAGCAA.

Fetal liver chimeras  {#s4-3}
---------------------

CD45.1 male mice from Charles River were used as recipients for fetal liver chimeras. Recipient mice were irradiated at 850 rads and fetal livers extracted from E15.5 wildtype or *Napa^hyh/hyh^* donor embryos were injected into 3 to 4 recipients each. At least 3 to 4 chimeras were analyzed per experiment and a total of 30 to 40 chimeras of each group were generated and analyzed as part of the entire study. All chimeras were analyzed 8 to 12 week post-reconstitution.

Technical and biological replicates {#s4-4}
-----------------------------------

Unless otherwise specified within figure legends, 'n' denotes technical as well as biological replicates. For instance, n = 3 means three technical repeats from three independent chimera pairs across 2 to 3 injections.

Cell isolation from chimeras and CD4 T cell sorting {#s4-5}
---------------------------------------------------

 For each experiment, spleen and lymph nodes were harvested from wildtype and *Napa^hyh/hyh^* fetal liver chimeras and subjected to two step sorting. CD4+ T cells were first enriched using MACS CD4+ T cell purification kit (Miltenyi Biotec Inc., San Diego, CA) according to manufacturer's instructions. CD4 T cell purity was routinely \>95%. To obtain unperturbed CD45.2+CD4+ double positive cells, MACS-enriched cells were stained with anti-CD45.1 APC and sorted using Aria II (BD Biosciences, San Jose, CA) by gating on CD45.1 negative cells.

Measurement of single cell SOCE and \[Ca^2+^\]~i~  {#s4-6}
--------------------------------------------------

CD45.2+CD4+ T lymphocytes were sorted from chimeras and plated on coverslips. Cells were loaded with 1 μM Fura-2-AM (Life Technologies, Eugene, OR) in Ringer's buffer (135 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 5.6 mM Glucose, and 10 mM Hepes, pH 7.4) for 40 min in the dark, washed, and used for imaging. Baseline images were acquired for 1 min and then cells were simulated with 10 μg/ml soluble anti-CD3 (Biolegend, San Diego, CA) plus 5 μg/ml secondary antibody (Biolegend) and imaged simultaneously in nominally calcium free Ringer's buffer for 5 to 6 min. Subsequently, extracellular calcium was replenished, and cells were imaged for an additional 5--6 min. 50 to 200 cells were analyzed per group in each experiment. An Olympus IX-71 inverted microscope equipped with a Lamda-LS illuminator (Sutter Instrument, Novato, CA), Fura-2 (340/380) filter set (Chroma, Bellows Falls, VT), a 10 × 0.3 NA objective lens (Olympus, UPLFLN, Japan), and a Photometrics Coolsnap HQ2 CCD camera was used to capture images at a frequency of \~1 image pair every 1.2 seconds. Data were acquired and analyzed using MetaFluor (Molecular Devices, Sunnyvale, CA), Microsoft Excel, and Origin softwares. To calculate \[Ca\]~i~, Fura-2 Calcium Imaging Calibration Kit (Life technologies) was used according to manufacturer\'s instructions. Briefly, standard samples containing dilutions of free Ca^2+^(0 to 39 μM) were imaged as described above to obtain the constant *K~d~*. \[Ca^2+^\]~i~ was then determined using the following equation:$$\lbrack Ca^{2 +}\rbrack = K_{d} \times \frac{\lbrack R - R_{min}\rbrack}{\lbrack R_{max} - R\rbrack} \times \frac{F_{max}^{380}}{F_{min}^{380}}$$

where R is the ratio of 510 nm emission intensity with excitation at 340 nm versus 380 nm; R~min~ is the ratio at zero free Ca^2+^; R~max~ is the ratio at saturating free Ca^2+^; F^380^~max~ is the fluorescence intensity with excitation at 380 nm, for zero free Ca^2+^; and F^380^~min~ is the fluorescence intensity at saturating free Ca^2+^. SOCE was calculated as (SOCE=highest \[Ca^2+^\]~i~ -- basal \[Ca^2+^\]~i~), where highest \[Ca^2+^\]~i~ was the highest value after replenishing extracellular calcium and basal \[Ca^2+^\]~i~ was the lowest \[Ca^2+^\]~i~, following store-depletion in calcium-free buffer. Percentage of average SOCE in *Napa^hyh/hyh^* or α-SNAP RNAi-treated samples was then determined by setting the average of wildtype SOCE to 100%.

Measurement of single cell \[Na\]~i~ {#s4-7}
------------------------------------

CD45.2+CD4+ T cells were sorted from chimeras, plated on coverslips and loaded with 2.5 μM SBFI-AM (Life Technologies) in Hank's balanced salt solution (HBSS) buffer at room temperature for 40 min in the dark, washed and used for imaging. Baseline images were acquired for 1 minute, and then cells were stimulated with 10 μg/ml soluble anti-CD3 (Biolegend) plus 5 μg/ml secondary antibody (Biolegend) and imaged simultaneously in HBSS buffer. SBFI was alternatively excited at 340 and 380 nm, and images were collected at 510 nm emission wavelength using the microscope setup described above. Nearly 150 cells were analyzed per group. To calculate \[Na^+^\]~i~, SBFI was calibrated in vivo in T lymphocytes based on the protocol described previously ([@bib44]; [@bib17]). Briefly, cells were loaded with SBFI and imaged in the buffer containing serial dilutions of free \[Na^+^\] concentration ranging from 0 and 150 mM, which were obtained by mixing Na^+^ free (130 mM potassium gluconate and 30 mM KCl) and Na^+^ MAX (130 mM sodium gluconate and 30 mM NaCl) solutions. To equilibrate extracellular and intracellular sodium, cells were treated with monovalent cation ionophore gramicidin D at 5 μM. After imaging cells in at least five dilutions, standard curve was obtained by plotting \[Na^+^\] on (x-axis) versus \[Na^+^\]/(1/R~0~-1/R) on (y-axis), where R is the ratio of emission intensity at 510 nm with excitation at 340 nm versus 380 nm; R~0~ is the ratio at zero Na^+^. From the above equation, the apparent *K~d~* of SBFI in T lymphocytes was obtained and \[Na^+^\]~i~ of experimental samples was then calculated using the constants derived from the regression line.

Intracellular ATP quantification {#s4-8}
--------------------------------

CD45.2+CD4+ T lymphocytes were sorted from chimeras and stimulated with 10 μg/ml anti-CD3, 5 μg/ml secondary antibody and 2 μg/ml anti-CD28 for indicated times. Subsequently, cells were washed using cold HBSS, pelleted and boiled in 100 μl TE buffer at 95°C for 5 to 7 minutes, and spun at 14000 RPM for 3 minute. Supernatants containing intracellular ATP and ATP standard were diluted using ATP assay solution according to manufacturer\'s instructions (ATP Determination Kit, Molecular Probes, Eugene, OR). Luminescence in standard and experimental samples was measured using FlexStation III, and intracellular ATP in experimental samples was calculated using ATP standard curve.

Whole cell lysates (WCLs), SDS-PAGE and Western blot  {#s4-9}
-----------------------------------------------------

CD45.2+CD4+ T lymphocytes were sorted from chimeras and stimulated with 10 μg/ml soluble anti-CD3 plus 5 μg/ml secondary antibody, and 2 μg/ml soluble anti-CD28 (Biolegend) in HBSS at 37°C for indicated times. Post-stimulation, cells were suspended in cold HBSS, pelleted down and lysed in RIPA buffer (Cell signaling, Danvers, MA). WCLs were boiled with Laemmli sample buffer containing 100 mM DTT and resolved using 10 or 12% SDS-polyacrylamide gel. Proteins were transferred by Western blotting to nitrocellulose membrane and probed with respective antibodies as described previously ([@bib42]). Antibodies used in this paper ([Source data 1](#SD4-data){ref-type="supplementary-material"}).

Nuclear and cytosolic extracts  {#s4-10}
-------------------------------

CD45.2+CD4+ T lymphocytes were sorted from chimeras and stimulated with 10 μg/ml soluble anti-CD3 (Biolegend) and 5 μg/ml secondary antibody along with 2 μg/ml soluble anti-CD28 (Biolegend) for 30 min. Cytoplasmic and nuclear extracts were prepared using (Thermo Scientific, Rockford, lL) NE-PER kit as per manufacturer\'s instructions and subjected to SDS-PAGE gel and Western blot as described previously ([@bib42]).

Gene expression analysis  {#s4-11}
-------------------------

Total RNA was extracted from cells by using RNeasy mini kit (QIAGEN, Germany), reverse transcribed to cDNA with M-MLV RT-PCR (Promega, Madison, WI) and used for Q-PCR. GAPDH and 18S rRNA were first used as housekeeping genes for normalization of expression. Because Ct values for GAPDH were closer to the Ct values of genes being analyzed here, final normalization was done using GAPDH.

RNA sequencing  {#s4-12}
---------------

CD45.2+CD4+ T lymphocytes were sorted from chimeras using MACS beads and BD Aria II and stimulated using plate-coated 10 μg/ml anti-CD3 along with 2 μg/ml soluble anti-CD28 for 6 hr. Following stimulation, total RNA was extracted by using RNeasy mini kit (QIAGEN) and submitted for quantification, library preparation, sequencing, and initial bioinformatics analysis to Genewiz (South Plainfield, NJ). Briefly, RNA samples were quantified using Qubit 2.0 Fluorometer (Life Technologies, Carlsbad, CA) and RNA integrity was checked with 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). Whole transcriptome RNA enrichment was performed using Ribozero rRNA Removal Kit (1:1 mixture of Human/Mouse/Rat probe and Bacteria probe) (Illumina, San Diego, CA). For RNA sequencing library preparation, NEB Next Ultra RNA Library Prep Kit for Illumina was used by following the manufacturer's recommendations (NEB, Ipswich, MA). Briefly, enriched RNAs were fragmented for 15 min at 94°C. First strand and second strand cDNA were subsequently synthesized. cDNA fragments were end repaired and adenylated at 3'ends, and universal adapter was ligated to cDNA fragments, followed by index addition and library enrichment with limited cycle PCR. Sequencing libraries were validated using a DNA Chip on the Agilent 2100 Bioanalyzer (Agilent Technologies), and quantified by using Qubit 2.0 Fluorometer (Invitrogen, Carlsbad, CA) as well as by quantitative PCR (Applied Biosystems, Carlsbad, CA).

The sequencing libraries were multiplexed, clustered on a single flow cell and loaded on the Illumina HiSeq 2500 instrument. Samples were sequenced using a 1 × 100 Single Read (SR) Rapid Run configuration. Image analysis and base calling were conducted using the HiSeq Control Software (HCS) on the HiSeq 2500 instrument. Raw sequence data (.bcl files) generated from Illumina HiSeq 2500 were converted into fastq files and de-multiplexed using Illumina bcl2fastq v1.8.4 program. One mismatch was allowed for index sequence identification. Gene expression analysis was performed using the CLC Genomics Workbench software, by trimming sequence reads to remove low-quality bases at ends, followed by mapping sequence reads to the mouse genome (Refseq) and calculating gene expression values as Reads Per Kilobase of transcript per Million mapped reads (RPKM). Gene expression data were further filtered to remove transcripts using the following criterion: (i) students t-test p value \> 0.05 between biological replicates, (ii) \<2 fold change, (iii) genes with \<10 total exon reads in wildtype group. The list of differentially expressed, filtered genes was deposited at Datadryad (<http://dx.doi.org/10.5061/dryad.202fn>). The data were also subjected to pathway analysis using the Metacore software (Thomson Reuters, NY) and top 50 pathways with a p-value\<0.05 are displayed in [Figure 6---source data 1](#SD3-data){ref-type="supplementary-material"}.

Intracellular cytokine staining  {#s4-13}
--------------------------------

Naïve or differentiated T cells were stimulated with PMA (20 ng/ml) and Ionomycin (1 μg/ml) and brefeldin A (Biolegend) for 5 to 6 hr and stained using anti-CD4 or anti-CD8 surface markers (Biolegend). Subsequently, cells were fixed and permeabilized and incubated with anti-IL-2, anti-IL-4 or anti-IFN-γ antibodies (Biolegend) and analyzed using FACS Calibur or LSR Fortessa analyzers and Flow Jo software (BD Biosciences).

T cell proliferations  {#s4-14}
----------------------

Naïve CD45.2+CD4+ T lymphocytes were sorted from chimeras and labeled with 10 μM CFSE, washed and stimulated with 5 μg/ml plate-coated anti-CD3 along with 2 μg/ml soluble anti-CD28 for 72 hr, stained with anti-CD4 antibody and analyzed using LSR Fortessa flowcytometer. In some experiments, unfractionated splenocytes were stimulated with soluble anti-CD3 and anti-CD28 for 48 hr, pulsed with 1 µCi ^3^H thymidine for additional 12--16 hr, harvested and counted.

Th1/Th2 differentiation  {#s4-15}
------------------------

CD4 T cells were purified from chimeras and stimulated with 5 μg/ml plate-coated anti-CD3 and 2 μg/ml soluble anti-CD28 in the presence of cytokines and neutralizing antibodies for 2 days. For Th1: 20 ng/ml IL-2, 20 ng/ml IL-12, 10 μg/ml anti-IL-4 and for Th2: 20 ng/ml IL-2, 50 ng/ml IL-4 was used. After 48 hrs cells were washed and cultured in the above cocktail of cytokines and antibodies for an additional three days. Cells were then stimulated with 20 ng/ml PMA, 1 μg/ml ionomycin and brefelin A (Biolegend) for 5--6 hr and stained for Th1/Th2 signature cytokines or transcription factors T-bet/Gata-3 as mentioned above.

Foxp3 Treg differentiation and staining  {#s4-16}
----------------------------------------

CD45.2+CD4+ T lymphocytes were sorted from chimeras and differentiated with 10 μg/ml plate coated anti-CD3, 2 μg/ml soluble anti-CD28 and 10 ng/ml TGF-β for five days and analyzed. Thymocytes, lymph node, splenocytes or in vitro differentiated Treg cells were stained with anti-CD4 and anti-CD25 surface markers, then fixed and permeabilized with Fix/Perm buffers (Biolegend) and stained with Alexa647-FoxP3 (Biolegend).

RNAi in primary T lymphocytes  {#s4-17}
------------------------------

α-SNAP targeting sequence, (CGCCAAAGACTACTTCTTCAA), was subcloned into MSCV-LTRmiR30-PIG retroviral vector (Openbiosystems, Lafayette, CO). Viral supernatants were made according to manufacturer\'s instruction. For infections, T cells were stimulated with anti-CD3 for 24 hr prior to infection and spun with the viral supernatant and polybrene (8 μg/ml) at high speed for 90 min. GFP positive cells were analyzed 3 day post infection.

T cell transfections  {#s4-18}
---------------------

Naïve T cells were transfected using Amaxa Mouse T Cell Nucleofector Kit (Lonza, Switzerland) according to manufacturer\'s instructions. Cells were analyzed \~16 hr post transfection.

Cell lines and transfection  {#s4-19}
----------------------------

HEK293 cells were obtained from (ATCC:CRL-1573)(RRID: [CVCL_0045](https://scicrunch.org/resolver/CVCL_0045)), expanded and cultured in DMEM containing 10% FBS, L-glutamine, non-essential amino acids and sodium pyruvate. Cells were co-transfected with CFP-Stim1 and YFP-α-SNAP or YFP-α-SNAP M105I expressing vectors, using Lipofectamine 2000 (Life technologies, USA) and imaged using TIRF illumination as described previously ([@bib42]). Cell line stocks were tested for mycoplasma contamination using Lonza Mycoalert (Lonza) every few years.

In vitro binding and western blotting  {#s4-20}
--------------------------------------

myc-tagged Orai1 and Stim1 proteins were immunoprecipitated from HEK293 (RRID: [CVCL_0045](https://scicrunch.org/resolver/CVCL_0045)) cells and beads were incubated with purified recombinant α-SNAP WT or M105I for 1 hr at 4°C. Post-incubation, beads were washed three times and protein complexes eluted by boiling in SDS containing sample buffer and subjected to SDS-PAGE and western blotting as described previously ([@bib42]).

Statistical analysis  {#s4-21}
---------------------

Statistical significance represented as p value was calculated using unpaired student's *t*-test, unless otherwise specified. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"T Cell Receptor Induced Na^+^ Influx Disrupts a Novel ATP → mTORC2 Signaling Node to Inhibit Regulatory T Cell Development\" for consideration by *eLife*. Your article has been favorably evaluated by Tadatsugu Taniguchi (Senior Editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission

Summary:

An α-SNAP hypomorphic mutation causing hydrocephalous with hopping gait (*hyh*) resulted in increased sodium influx in TCR-stimulated T cells, which induced ATP reduction and blocked AKT-mTORC2 signaling. This altered T-cell signaling impaired T-cell cytokine production and Treg cell development, showing a novel regulatory mechanism of Treg and T cell differentiation.

Essential revisions:

1\) The authors claim that sodium influx affected not only Treg development but also Treg function. Defective Treg development was demonstrated, whereas the analysis of Treg function was not enough. The expression levels of Treg signature molecules, such as CTLA4, GITR and Helios, on *hyh* Treg cells should be assessed. As shown in [Figure 2](#fig2){ref-type="fig"}, the colitis model indicates *hyh* T cell-mediated inflammation was more severe than WT naïve T cell transfer. To evaluate the contribution of Treg, they should conduct co-transfer experiments with *hyh* or WT Tregs together with WT CD45RA-high CD4^+^ T cells, and assess Treg number and phenotype (expression of Treg functional molecules) of Foxp3+ cells. The authors also need to perform in vitro suppression assay to assess the function of *hyh* Treg cells.

2\) Regarding the effects of the SNAP mutation on non-Treg cells, effector function of non-Treg cells should be tested in some experiments. [Figure 1L](#fig1){ref-type="fig"} indicates T-bet or GATA3 was higher in expression in *hyh* T cells. Thus, the authors should examine whether the development of in vitro iTreg is inhibited by these effector transcription factors. Additionally, *hyh* T cell transfer caused more severe pathology than WT cell transfer, although *hyh* T cells appeared to be defective in production of effector cytokines according to [Figure 1](#fig1){ref-type="fig"}. To address this discrepancy, the effector phenotype of T cells in vivo, such as cytokine production or T cell activation marker expression, should be evaluated in the colitis model.

3\) This study proposes that increased sodium entry leads to reduced ATP levels in activated T cells that results in decreased MTORC2 activation. This would cause defective PKC-theta and NFkB activity that would lead to defective differentiation and function of Tregs. However, the data that shows that decreased MTORC2 activation due to reduced ATP prevents full NFkB activation is only correlative. To establish cause-effect, experiments would need to be designed to show the functional connection between all those observations. For example, would the defect in MTORC2 activation be bypassed by expressing a constitutively active PKC-theta? Or will the functional defects in those T cells be corrected by activating NFkB (for instance using an active form of IKK)? Nuclear translocation of p65 is independent of Orai1-mediated SOCE as suggested by [Figure 3K](#fig3){ref-type="fig"}. If so, how about activations of upstream kinases or complex formation of adaptor molecules in *hyh* T cells? In addition, the authors should evaluate other NF-κB family proteins, especially c-rel. Also, can an ATP analog or an AKT activator (or constitutively active AKT) recover the reduction of in vitro iTreg development shown in [Figure 2I](#fig2){ref-type="fig"}? To examine whether sodium influx reduces AKT activation by the depletion of intracellular ATP, it is necessary to show S473 phosphorylation in the presence of Digoxin or NMDG. How about silencing of Foxo1? With the demonstration that SNAP reconstitution improved the defects of IL-2 production in [Figure 6C](#fig6){ref-type="fig"}, does it improve iTreg development?

4\) The authors use monensin as the inducer of sodium influx, but monensin has many other biological functions such as inhibition of protein transport. For example, in [Figure 5B](#fig5){ref-type="fig"}, they need to confirm that AKT pT308 is not affected by monensin, even though AKT pS473 is decreased. In addition, the effect of monensin on the iTreg development ([Figure 3N](#fig3){ref-type="fig"}) is striking compared to the effect of SNAP mutation as shown in [Figure 2I](#fig2){ref-type="fig"}, despite a similar degree of sodium influx and ATP reduction. The authors need to address whether the monensin-mediated inhibition can be rescued by AKT activator or ATP treatment.

5\) While it is true that NFAT does not seem to be required for the generation of tTregs, the Vaeth et al. study showed an important decrease in the generation of pTregs in mice deficient in NFATc1 and NFTAc2. It might be difficult then to conclusively determine if the decreased generation of pTregs (or iTregs) is due to increased Na entry or decreased SOCE in *hyh* T cells.

10.7554/eLife.25155.018

Author response

*Essential revisions:*

*1) The authors claim that sodium influx affected not only Treg development but also Treg function. Defective Treg development was demonstrated, whereas the analysis of Treg function was not enough. The expression levels of Treg signature molecules, such as CTLA4, GITR and Helios, on hyh Treg cells should be assessed. As shown in [Figure 2](#fig2){ref-type="fig"}, the colitis model indicates hyh T cell-mediated inflammation was more severe than WT naïve T cell transfer. To evaluate the contribution of Treg, they should conduct co-transfer experiments with hyh or WT Tregs together with WT CD45RA-high CD4^+^ T cells, and assess Treg number and phenotype (expression of Treg functional molecules) of Foxp3+ cells. The authors also need to perform in vitro suppression assay to assess the function of hyh Treg cells.*

The colitis experiment was performed to evaluate CD4 T cell function in vivo and the phenotype we have observed can have several explanations, in addition to a defect in pTreg development and function. For instance, even though hyh CD4 T cell development was not obviously disrupted, repertoires as well as signaling thresholds could be altered as a result of several signaling and gene expression defects that we have found in *hyh* CD4 T cells. Future studies using *hyh* mice crossed to various TCR transgenic mice will allow us to differentiate between these possibilities in a concrete fashion.

We agree that Treg function was not directly assessed in this paper and have removed the colitis experiment from [Figure 2](#fig2){ref-type="fig"} because extrapolation of the colitis model to Treg function is not a direct experiment to establish Treg function. We have modified the text and Discussion which now refers to Treg differentiation but not function. Future studies using adoptive co-transfers of WT and hyh Foxp3 Tregs using more classical models of assessment of Foxp3 Treg function will allow us to address the in vivo function of WT *vs hyh* Foxp3 Tregs.

Regarding surface expression of functional markers of Treg, we have found a partial but consistent defect in the surface expression of GITR in *hyh* Foxp3 Tregs. In addition, RNA sequencing of CD4 T cells revealed reduced expression of ICOS and LAG-3 in receptor activated *hyh* CD4 T cells. These data have been added to [Figure 2E](#fig2){ref-type="fig"} and [Figure 6H](#fig6){ref-type="fig"} respectively and suggest that there may be additional functional/ homing/ expansion defects in *hyh* Foxp 3 Tregs in vivo. Again, future studies will assess *hyh* Treg function.

*2) Regarding the effects of the SNAP mutation on non-Treg cells, effector function of non-Treg cells should be tested in some experiments. [Figure 1L](#fig1){ref-type="fig"} indicates T-bet or GATA3 was higher in expression in hyh T cells. Thus, the authors should examine whether the development of in vitro iTreg is inhibited by these effector transcription factors. Additionally, hyh T cell transfer caused more severe pathology than WT cell transfer, although hyh T cells appeared to be defective in production of effector cytokines according to [Figure 1](#fig1){ref-type="fig"}. To address this discrepancy, the effector phenotype of T cells in vivo, such as cytokine production or T cell activation marker expression, should be evaluated in the colitis model.*

T-bet and GATA-3 levels were not significantly different between experimental repeats. The average from three experiments is now shown in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}. It is unclear why we do not see a decrease in GATA-3 levels despite a significant defect in mTORC2 signaling and IL-4 expression. One possibility is that another unknown factor/ binding partner prevents its turnover in *hyh* T cells.

[Figure 1](#fig1){ref-type="fig"} shows that the defect in the expression of IFN-γ was only about 50% in *hyh* CD4 T cells. By contrast, the defect in IL-2 and the Th2 signature cytokine, IL-4, was much larger (See selected genes in [Figure 6H](#fig6){ref-type="fig"}). Defective mTORC2 signaling could explain a relatively bigger defect in IL-4 expression in *hyh* CD4 T cells when compared to *Orai1-/-* mice. In this regard, our findings are in good agreement with previously published defects in *Orai1-/-* and Rictor-/- mice respectively (Vig, et al. Nat Imm. 2008; Gwack et al. MCB 2008; Lee et al. Immunity 2010; Delgoffe et al. Nat Immunol 2011).

Because IFN-γ is a major driver of colitis in the T cell adoptive transfer model, a 50% defect in its expression by *hyh* CD4 T cell effectors could easily have been compensated by several factors in vivo. For instance, the gut microenvironment is especially enriched in extracellular ATP, which has been shown to act as an adjuvant in vivo and drive inflammation (Atarashi et al. Nature, 2008; Borsellino et al. Blood 2007). Extracellular ATP could bind P2X receptors and induce calcium influx in *hyh* T cells in vivo, to bypass the defect in *hyh* CD4 T cell SOCE and IFN-γ production. It is therefore not unreasonable to speculate that depending on the environment, stimulus and levels of extracellular ATP, partial defects in SOCE can be compensated in vivo.

Future studies should be able to assess the in vivo effector function of *hyh* CD4 T cells in response to antigen specific stimulation after crossing *hyh* mice to various different TCR transgenic mice and also test their function in specific disease models.

*3) This study proposes that increased sodium entry leads to reduced ATP levels in activated T cells that results in decreased MTORC2 activation. This would cause defective PKC-theta and NFkB activity that would lead to defective differentiation and function of Tregs. However, the data that shows that decreased MTORC2 activation due to reduced ATP prevents full NFkB activation is only correlative. To establish cause-effect, experiments would need to be designed to show the functional connection between all those observations.*

MTORC2 mediated NFkB activation in CD4 T cells has been demonstrated by Lee et al. Immunity 2010, using Rictor-/- mice. Therefore, re-establishing cause-effect in the signaling pathway downstream of mTORC2 in CD4 T cells is going to be redundant with published literature.

Furthermore, downstream of mTORC2, NFkB can be activated by several independent routes i.e. via AKT, PKC-theta or directly via phosphorylated IKK. These routes of activation NFkB could be fully or partially redundant. Therefore, establishing cause-effect and functional connection using NFkB activators or by depleting individual upstream regulators of NFkB will affect several parallel and unrelated pathways.

Still, we have found that depleting Orai1 in *hyh* CD4 T cells reverses IκB-α phosphorylation. These data have been added to [Figure 6D](#fig6){ref-type="fig"}.

*For example, would the defect in MTORC2 activation be bypassed by expressing a constitutively active PKC-theta? Or will the functional defects in those T cells be corrected by activating NFkB (for instance using an active form of IKK)?*

Please see our response above as well as below. First, the experiments suggested here have already been done by Lee at al. Immunity 2010. A major finding of our paper is the identification of \[ATP\]~i~ as the upstream regulator of mTORC2 in CD4 T cells and its sensitivity to non-specific Na influx via Orai1 and this has been established conclusively in the paper.

*Nuclear translocation of p65 is independent of Orai1-mediated SOCE as suggested by [Figure 3K](#fig3){ref-type="fig"}. If so, how about activations of upstream kinases or complex formation of adaptor molecules in hyh T cells?*

We have found that in addition to PKC-theta, phosphorylation of IKK-β and IκB-α was also defective in *hyh* CD4 T cells. These data have now been added to [Figure 6B,C and D](#fig6){ref-type="fig"} and updated in the model in [Figure 8](#fig8){ref-type="fig"}. We have also found that depleting Orai1 reverses IKB-α phosphorylation ([Figure 6D](#fig6){ref-type="fig"}). However, given the potential redundancy among upstream kinases that activate NFkB, establishing a cause-effect connection can be quite complex. For instance, previous studies have shown that mTORC2 can activate PKC-theta in CD4 T cells (Lee et al. 2010). However, NFκB has also been shown to be directly activated downstream of mTORC2 in Gliobalstoma cells (Tanaka et al. Cancer Discov. 2011).

*In addition, the authors should evaluate other NF-κB family proteins, especially c-rel.*

c-rel phosphorylation was defective in *hyh* CD4 T cells. The data have been added to [Figure 3I](#fig3){ref-type="fig"}.

*Also, can an ATP analog or an AKT activator (or constitutively active AKT) recover the reduction of in vitro iTreg development shown in [Figure 2I](#fig2){ref-type="fig"}?*

We are unaware of any cell permeable ATP analogs. In our hands, extracellular ATP cannot cross plasma membrane to compensate for the defects in ATP levels in *hyh* CD4 T cells (data not shown).

AKT is a repressor of thymic as well as iTreg differentiation (Haxinasto, S JEM, 2008). Therefore, it is unlikely that an AKT activator will compensate for the defects in iTreg development. We therefore think that reduced activation of AKT pS473 could be partially reversing or compensating for the severe defects in NFkB activation and Treg differentiation by stabilization of FOXO-1 in the nucleus.

*To examine whether sodium influx reduces AKT activation by the depletion of intracellular ATP, it is necessary to show S473 phosphorylation in the presence of Digoxin or NMDG.*

Digoxin not only inhibits Na K ATPase but has also been shown to directly binds ROR-γ T and influence TH17 differentiation (Huh, JR and Littman, D Nature 2011). The suggested experiment would therefore be difficult to interpret.

NMDG non-specifically blocks all types Na influx even in resting cells. This would block Na influx even via leak channels, which is detrimental for cells beyond short periods of time as it may disrupt the activity of many other ion channels. For this reason, we decided to deplete Orai1 expression in *hyh* CD4 T cells. Because Orai1 ablation largely blocked non-specific Na influx in TCR *hyh* T cells, it is a better, specific and much more conclusive experiment.

*How about silencing of Foxo1?*

FOXO-1 plays many different roles in T cells. It has been recently shown that graded activation of FOXO-1 is required for Foxp3 Treg activation (Luo et al. Nature 2016). FOXO-1 has also been reported to have a cytosolic role in hematopoietic differentiation (Wang et al. Nature Comm. 2016). It is currently unclear whether pharmacological inhibition of FOXO-1 acts in the same fashion as its deletion (Laine et a. JI, 2015; Kitz, A Embo 2016). Therefore, inhibiting or silencing FOXO-1 completely in *hyh* CD4 T cells is likely to yield ambiguous results. More so, because, we have only observed a partial defect in nuclear export of FOXO-1, it is therefore unclear how silencing it in *hyh* CD4 T cells will strengthen the main point of the paper. Perhaps for these reasons, although we do see upregulation of a few FOXO-1 target genes in [Figure 6H](#fig6){ref-type="fig"}, others such as CTLA4 did not show up in our RNA sequencing analysis.

Because the Treg differentiation defect can be easily explained by a robust defect in NFkB, we have removed the AKT/FOXO-1 axis from our model in [Figure 8](#fig8){ref-type="fig"}, as this was not clearly established in our paper. Future studies may address its role, if any, in *hyh* CD4 T cells.

*With the demonstration that SNAP reconstitution improved the defects of IL-2 production in [Figure 6C](#fig6){ref-type="fig"}, does it improve iTreg development?*

Unlike, IL-2 production (6 hour assay), iTreg differentiation requires 3-4 days of culture and stable expression. Therefore, we used retroviral reconstitution of α-SNAP expression in *hyh* CD4 T cells to address this question. However, due to technical issues which are likely due to the iTreg differentiation protocol, SNAP reconstitution efficiency was \<5% in *hyh* CD4 T cells or if we modified the protocol in any way, we were unable to differentiate Foxp3 iTregs even in WT CD4 T cells. We have not been able to troubleshoot these technical issues.

*4) The authors use monensin as the inducer of sodium influx, but monensin has many other biological functions such as inhibition of protein transport. For example, in [Figure 5B](#fig5){ref-type="fig"}, they need to confirm that AKT pT308 is not affected by monensin, even though AKT pS473 is decreased. In addition, the effect of monensin on the iTreg development ([Figure 3N](#fig3){ref-type="fig"}) is striking compared to the effect of SNAP mutation as shown in [Figure 2I](#fig2){ref-type="fig"}, despite a similar degree of sodium influx and ATP reduction. The authors need to address whether the monensin-mediated inhibition can be rescued by AKT activator or ATP treatment.*

Monensin treatment did not affect AKT pT308. These data have been added to the same figure (now [Figure 6D](#fig6){ref-type="fig"}). We agree that monensin has several other effects besides increasing intracellular Na levels. Therefore, we have now shown a dose response in the inhibition of differentiation of iTreg with monensin ([Figure 3S](#fig3){ref-type="fig"}).

We are unaware of any cell permeable ATP analogs. In our hands, extracellular ATP cannot cross the plasma membrane to compensate for depletion of intracellular ATP (data not shown).

AKT is a repressor of thymic as well as iTreg differentiation (Haxinasto, S JEM, 2008). Therefore, it is unlikely that AKT activator will compensate for the defects in iTreg development in monensin treated cells. Furthermore, monensin also has several other effects in addition to inducing Na influx. Monensin was used here just to support our findings and conclusions in *hyh* CD4 T cells.

5\) While it is true that NFAT does not seem to be required for the generation of tTregs, the Vaeth et al. study showed an important decrease in the generation of pTregs in mice deficient in NFATc1 and NFTAc2. It might be difficult then to conclusively determine if the decreased generation of pTregs (or iTregs) is due to increased Na entry or decreased SOCE in hyh T cells.

We did not find any reduction in iTreg generation in Orai1 depleted CD4 T cells that also show a significant decrease in SOCE and NFAT translocation ([Figure 3O](#fig3){ref-type="fig"}). Therefore, it is reasonable to conclude that a partial defect in SOCE alone does not reduce iTreg generation. Therefore, in *hyh* CD4 T cells, Foxp3 Treg differentiation defect largely results from increased sodium entry and the downstream defects in NFkB signaling.
